Capital Group Investment Management PTE. LTD. Purchases 420 Shares of BioNTech SE (NASDAQ:BNTX)

Capital Group Investment Management PTE. LTD. boosted its position in shares of BioNTech SE (NASDAQ:BNTX) by 9.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,697 shares of the company’s stock after purchasing an additional 420 shares during the period. Capital Group Investment Management PTE. LTD.’s holdings in BioNTech were worth $433,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BNTX. Harding Loevner LP purchased a new stake in shares of BioNTech in the fourth quarter worth approximately $410,984,000. Primecap Management Co. CA boosted its stake in shares of BioNTech by 2.8% during the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after purchasing an additional 131,490 shares during the period. DekaBank Deutsche Girozentrale grew its holdings in shares of BioNTech by 43.1% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 425,071 shares of the company’s stock worth $44,610,000 after purchasing an additional 127,951 shares during the last quarter. abrdn plc bought a new position in shares of BioNTech in the fourth quarter worth about $10,961,000. Finally, Baillie Gifford & Co. lifted its holdings in BioNTech by 1.0% during the 4th quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock valued at $917,056,000 after buying an additional 86,343 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on BNTX shares. Evercore ISI began coverage on shares of BioNTech in a research note on Tuesday, May 14th. They issued an “inline” rating and a $100.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $113.00 price objective on shares of BioNTech in a research note on Wednesday, June 26th. TD Cowen lifted their target price on BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a research report on Tuesday, May 7th. Finally, BMO Capital Markets dropped their price target on BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 7th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $111.70.

BioNTech Stock Up 1.5 %

NASDAQ:BNTX traded up $1.26 during midday trading on Friday, reaching $85.94. 264,744 shares of the stock traded hands, compared to its average volume of 691,346. The business has a 50-day moving average of $89.32 and a two-hundred day moving average of $91.59. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. BioNTech SE has a 12-month low of $78.02 and a 12-month high of $125.83. The stock has a market capitalization of $20.43 billion, a PE ratio of 171.88 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.60). BioNTech had a return on equity of 0.55% and a net margin of 4.01%. The business had revenue of $203.69 million for the quarter, compared to analysts’ expectations of $589.96 million. On average, equities analysts forecast that BioNTech SE will post -2 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.